LENZ Therapeutics, Inc.

NasdaqGS:LENZ Stock Report

Market Cap: US$283.8m

LENZ Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:LENZ Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
27 Mar 26BuyUS$64,275Daniel ChevallardIndividual7,500US$8.57
27 Mar 26BuyUS$251,411Evert SchimmelpenninkIndividual28,089US$8.95
27 Mar 26BuyUS$49,890Jeffrey GeorgeIndividual5,592US$8.92
07 Nov 25BuyUS$50,017Daniel ChevallardIndividual2,198US$22.76
07 Nov 25BuyUS$239,278James McCollumIndividual10,500US$22.79
30 Sep 25SellUS$10,352,017Versant Venture Management, LLCCompany224,974US$47.01
18 Sep 25SellUS$5,714,356Versant Venture Management, LLCCompany135,304US$43.30
18 Sep 25SellUS$13,138,276Versant Venture Management, LLCCompany323,398US$42.23
26 Aug 25SellUS$7,423,920Versant Venture Management, LLCCompany188,094US$40.59
18 Aug 25SellUS$10,255,244Versant Venture Management, LLCCompany260,713US$39.50
10 Jul 25SellUS$6,506,784Versant Venture Management, LLCCompany191,376US$34.00
27 Jun 25SellUS$6,093,000Versant Venture Management, LLCCompany200,000US$30.47
20 Jun 25SellUS$10,107,818Versant Venture Management, LLCCompany334,801US$30.35
10 Jun 25SellUS$10,150,000Versant Venture Management, LLCCompany350,000US$29.00

Insider Trading Volume

Insider Buying: LENZ insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of LENZ?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders831,1982.2%
Hedge Funds5,205,45713.8%
VC/PE Firms6,835,71118.1%
Institutions24,967,27666%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 97.56% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.3%
RA Capital Management, L.P.
4,178,823US$37.8m0%0.57%
11.8%
FMR LLC
3,699,953US$33.5m4,140%no data
11.5%
Alpha Wave Global, LP
3,612,211US$32.7m0%1.89%
8.47%
Versant Venture Management, LLC
2,656,888US$24.0m0%13.48%
5.75%
BlackRock, Inc.
1,804,088US$16.3m6.62%no data
5.08%
Squarepoint OPS LLC
1,593,246US$14.4m224%0.03%
5.07%
UBS Asset Management AG
1,590,589US$14.4m31.1%no data
4.21%
The Vanguard Group, Inc.
1,321,202US$12.0m-0.68%no data
3.48%
Franklin Resources, Inc.
1,090,039US$9.9m98.4%no data
3.26%
T. Rowe Price Group, Inc.
1,023,542US$9.3m308%no data
3.25%
Point72 Asset Management, L.P.
1,017,751US$9.2m-25%0.01%
2.76%
Tang Capital Management, LLC
865,169US$7.8m-3.61%0.4%
2.01%
James McCollum
631,099US$5.7m1.69%no data
1.82%
Intrinsic Edge Capital Management LLC
569,705US$5.2m0%0.92%
1.72%
Millennium Management LLC
539,348US$4.9m0%no data
1.63%
State Street Global Advisors, Inc.
510,749US$4.6m22.2%no data
1.59%
C WorldWide Asset Management Fondsmaeglerselskab A/S
500,000US$4.5m0%0.05%
1.56%
Aberdeen Group Plc
489,432US$4.4m274%no data
1.48%
Alyeska Investment Group, L.P.
463,495US$4.2m91.4%0.01%
1.47%
Geode Capital Management, LLC
461,075US$4.2m1.36%no data
1.37%
Granahan Investment Management, LLC
431,100US$3.9m125%0.18%
1.27%
Nomura Investment Management Business Trust
398,566US$3.6m0%no data
1.25%
Medical Strategy GmbH
393,047US$3.6m0%0.25%
1.2%
Candriam, Société En Commandite Par Actions
374,932US$3.4m63.8%0.01%
1.19%
PRIMECAP Management Company
372,200US$3.4m0%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/30 11:18
End of Day Share Price 2026/04/30 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

LENZ Therapeutics, Inc. is covered by 9 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Yigal NochomovitzCitigroup Inc
Matthew CaufieldH.C. Wainwright & Co.